Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus SERPASIL ESIDRIX 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus SERPASIL ESIDRIX 1.
ALDORIL 25 vs SERPASIL-ESIDRIX #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination